One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

Alumis’ most advanced product candidate, ESK-001, is an oral, highly selective, small molecule, allosteric inhibitor of tyrosine kinase 2 that is currently being evaluated for the treatment of ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...

Furthermore, 27% of all patients needed assistance with their psoriasis treatment. The authors cited study limitations such ...

One specific type of viral exanthem that dermatologists have seen with COVID is a morbilliform rash, meaning a measles-like rash. Measles rashes tend to look like small raised bumps that eventually ...

Study authors examined the use of artificial intelligence in machine learning models for the assessment of psoriasis severity, as well as identified future research needs.

Researchers from the National Defense Medical Center in Taiwan have identified an increased risk of psoriasis in patients ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...

Organon (OGN) stock on watch as FDA delays a potential label expansion for its VTAMA cream, impacting 2025 EBITDA margin and ...

Medically reviewed by Doru Paul, MD To confirm a psoriasis diagnosis, your healthcare provider will check your skin and scalp ...